CYT — Cyteir Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $111.95m
- -$17.29m
- 44
- 35
- 77
- 51
Annual income statement for Cyteir Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.008 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 16.1 | 20.9 | 42.3 | 48.2 |
| Operating Profit | -16.1 | -20.9 | -42.3 | -48.2 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -15 | -20.8 | -42.1 | -46.1 |
| Net Income After Taxes | -15 | -20.8 | -42.1 | -46.1 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -15 | -20.8 | -42.1 | -46.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -15 | -20.8 | -42.1 | -46.1 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.436 | -0.604 | -1.2 | -1.31 |
| Dividends per Share |